B Cell Lymphoma
From the Journals
ASCT may cure follicular lymphoma for some rituximab-naive patients
A retrospective cohort study suggests that ASCT, if performed promptly, can be curative in patients who have had an early failure of first-line...
From the Journals
CAR T-cell therapy found safe, effective for HIV-associated lymphoma
Two HIV-positive patients with chemotherapy-refractory, high-grade B-cell lymphoma achieved complete remission with anti-CD19 CAR T-cell therapy,...
From the Journals
Staging PET/CT better defines extent of mantle cell lymphoma
This type of imaging altered stage and management in nearly one-fifth of cases.
Feature
Could home care replace inpatient HSCT?
Researchers are conducting phase 2 trials comparing patients who receive all posttransplant care at home with patients treated in the hospital or...
From the Journals
Study confirms prognostic impact of MYC partner gene in DLBCL
The findings suggest that clinicians should adopt diagnostic strategies to identify this high-risk cohort of patients.
From the Journals
Rituximab, bendamustine look better than chemo alone in MCL
The research confirms the benefit of adding novel agents to chemotherapy regimens in older patients with mantle cell lymphoma.
From the Journals
CK doesn’t seem to affect OS in CLL patients taking idelalisib
Data from two clinical trials of idelalisib showed no significant difference in overall survival between patients with and without complex...
Conference Coverage
Ibrutinib-rituximab induction yields ‘unprecedented’ responses in MCL
LUGANO, SWITZERLAND – In patients younger than 65 years old, two cycles of ibrutinib and rituximab followed by four cycles of chemotherapy...
News
Calquence earns breakthrough designation for CLL monotherapy
The Bruton tyrosine kinase inhibitor is already approved for the treatment of adults with mantle cell lymphoma who have received at least one...
From the Journals
Obinutuzumab-lenalidomide combo shows promise in relapsed/refractory FL
In the phase 2 GALEN study, induction with obinutuzumab and lenalidomide followed by maintenance therapy with obinutuzumab appears effective for...
From the Journals
Brentuximab vedotin plus nivolumab shows positive outcomes in PMBL
The CheckMate 436 study showed that the combination may be synergistic and is highly active in relapsed/refractory primary mediastinal B-cell...